Safety Clinical Trial
Official title:
A Double Blind, Randomized, Placebo Controlled, Two Part, Two Session Balanced, Crossover Study to Evaluate Visual Changes in Healthy Male Subjects Aged 18 - 55 Years After Receiving: 1. at Least 15 Doses of 20 mg Vardenafil, Compared to Placebo and 2. Two Doses of Sildenafil, 200 mg Compared to Placebo
Vardenafil (Levitra) and Sildenafil (Viagra) are drugs that are marketed for use in patients with erectile dysfunction. The purpose of this study is to find out if there are any changes in the eye after taking at least 15 doses of Vardenafil and after two doses of Sildenafil. This is a double-blind study, which means that neither you nor the study doctor will know which treatment you are receiving. If you qualify for the study, you will receive:- Vardenafil 20 mg twice per week (Monday and Thursday) for a maximum of 8 weeks. There will be two times when this occurs during the study.- Sildenafil 200 mg/day for two days. There will be two times when this occurs during the study. - Placebo (a pill that looks like vardenafil or sildenafil but has no active ingredient).
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05073744 -
Nalbuphine Versus Morphine for Perioperative Tumor Ablation
|
Phase 4 | |
| Completed |
NCT03969641 -
Safety of RIV4 Versus IIV4 in Pregnant Women
|
Phase 4 | |
| Completed |
NCT05592951 -
Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers
|
N/A | |
| Completed |
NCT04693429 -
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
|
Phase 1 | |
| Completed |
NCT01636024 -
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
|
Phase 1 | |
| Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
| Completed |
NCT01243502 -
A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT06072170 -
Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience
|
Phase 1 | |
| Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06060379 -
Giochiamo 626 - Gaming for Health and Safety in Workplaces
|
N/A | |
| Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
| Completed |
NCT05188638 -
Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT05145621 -
Oral Bio-equivalence Study
|
Phase 1 | |
| Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
| Not yet recruiting |
NCT04596956 -
Safety and Efficacy of Sodium Bicarbonate Ringer Injection
|
Phase 4 | |
| Completed |
NCT03033329 -
Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4
|
Phase 1 | |
| Terminated |
NCT01929811 -
NeoMET Study in Neoadjuvant Treatment of Breast Cancer
|
Phase 2 | |
| Completed |
NCT01193335 -
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
|
Phase 4 | |
| Completed |
NCT03300466 -
A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds
|
N/A | |
| Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 |